Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis
In our cohort of young children with CF, early and persistent ABT use was not associated with significant growth benefits and instead showed associations with reduced GM diversity and negative effects on early-onset lung disease. Consequentially, there is a critical need for systematic evaluation and comprehensive risk-benefit analysis of ABT to ensure proper guidelines for children with CF.
Authors
- Xiaoyue Cathy Liu (ORCID: https://orcid.org/0000-0002-5162-891X)
- Fadi Asfour (ORCID: https://orcid.org/0000-0001-6317-6845)
- HuiChuan J. Lai (ORCID: https://orcid.org/0000-0001-8084-3988)
- Michael J. Rock (ORCID: https://orcid.org/0000-0001-9665-1737)
- Michelle S. Howenstine
- Nicholas Antos (ORCID: https://orcid.org/0000-0002-7380-120X)
- Jonathan M. Gaffin (ORCID: https://orcid.org/0000-0003-2213-4504)
- Philip M. Farrell (ORCID: https://orcid.org/0000-0003-0036-7016)
- Derek M. Pavelec (ORCID: https://orcid.org/0000-0002-3039-3664)
- Taiya R. Bach
Institutions
- Boston Children's Hospital (US)
- University of Wisconsin System (US)
- University of Wisconsin–Madison (US)
- Medical College of Wisconsin (US)
- University of Utah (US)
- University of Wisconsin Health (US)
- Wisconsin Division of Public Health (US)
- Indiana University Indianapolis (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Journal of Pediatric Gastroenterology and Nutrition
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1002/jpn3.12389
- Citations
- 2
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Cystic Fibrosis Foundation
- University of Wisconsin-Madison
- Northwestern University
- Harvard University
- National Institutes of Health
- School of Medicine and Public Health, University of Wisconsin-Madison